Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 4, 2013, Pages 266-272

  Herbild, Louise ^a   Andersen, Stig E ^b   Werge, Thomas ^c   Rasmussen, Henrik B ^c   Jürgens, Gesche ^b  

^a Amgros   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Copenhagen University Hospital ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE COST; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MENTAL HOSPITAL; PHARMACOGENETICS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DENMARK; FEMALE; GENOTYPE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84883746349     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12093     Document Type: Article

References (24)

1. Chou WH, Yan FX, De Leon J, Barnhill J, Rogers T, Cronin M et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000;20:246-51.
2. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34.
3. Olgiati P, Serretti A, Bigelli M, De Ronchi D, Bajo E. Is pharmacogenetic testing ready for antidepressant treatment? A costeffectiveness simulation. Eur Neuropsychopharmacol 2011;21:S389.
4. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 2011;1-15. [Early Online].
5. Herbild L, Bech M, Gyrd-Hansen D, Christensen M, Werge T, Nielsen KA. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services? Scand J Public Health 2011;39:147-55.
6. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007;81:899-902.
7. Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004;65:1211-8.
8. Rettenbacher M, Burns T, Kemmler G, Fleischhacker WW. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry 2004;37:103-9.
9. Wilke RA, Musana AK, Weber WW. Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. Pers Med 2005;2:213-24.
10. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
11. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73.
12. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
13. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 2006;66:129-36.
14. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008;83:322-7.
15. Bijl MJ, Visser LE, Hofman A, Vulto AG, van GT, Stricker BH et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008;65:558-64.
16. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386-93.
17. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009;59:222-6.
18. Serretti A. Pharmacogenomics of psychotropic drugs. Pharmacogenomics 2011;12:1509-10.
19. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011;36:87-113.
20. Munk-Jorgensen P, Mortensen PB. The Danish psychiatric central register. Dan Med Bull 1997;44:82-4.
21. Psykiatrisk Center Sankt Hans. CYP-test Region H. http://www.psykiatri-regionh.dk/menu/Centre/Psykiatriske+centre/Psykiatrisk+Center+Sct.+Hans/Forskning+og+kvalitet/Forskningsinstitut+for+Biologisk+Psykiatri/CYPtest.htm. (last accessed on 29 July 2010).
22. Kolonien Filadelfia. Laboratoriet i Dianalund [The laboratory at Dianalund]. http://laboratoriet.epilepsihospitalet.dk/. (last accessed on 9 August 2007).
23. Wittchen H, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76.
24. Jurgens G, Jacobsen CB, Rasmussen HB, Werge T, Nordentoft M, Andersen SE. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice. Acta Psychiatr Scand 2012;125:228-37.